Belatacept Conversion in Kidney Transplant: With or without Calcineurin Inhibitor Taper

被引：0
|
作者：
Elmasri, A. [1 ]
Valdepenas, B. [1 ]
Benken, S. [1 ]
Hajjiri, Z. [2 ]
Benken, J. [1 ]
机构：
[1] Univ Illinois, Chicago, IL USA
[2] Univ Illinois Hosp & Hlth Sci Syst, Chicago, IL USA
来源：
AMERICAN JOURNAL OF TRANSPLANTATION | 2023年 / 23卷 / 06期
关键词：
D O I：
暂无
中图分类号：
R61 [外科手术学];
学科分类号：
摘要：
B202
引用
下载
收藏
页码：S845 / S846
页数：2
相关论文
共 50 条
  • [21] Safety and Efficacy of Belatacept Conversion Following Kidney Transplant
    Bixby, A.
    Hampton, A.
    Ecabert, D.
    Burrelli, C.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2023, 23 (06) : S850 - S850
  • [22] Belatacept Conversion Protocols and Outcomes in Kidney Transplant Recipients
    Yazdi, Mona
    Kahwaji, Joseph M.
    Meguerditchian, Sam
    Lee, Roland
    TRANSPLANTATION PROCEEDINGS, 2021, 53 (03) : 976 - 983
  • [23] 3-YEAR OUTCOMES AFTER SWITCHING TO BELATACEPT FROM A CALCINEURIN INHIBITOR IN STABLE KIDNEY TRANSPLANT RECIPIENTS
    Kamar, Nassim
    Rial, Maria
    Alberu, Josefina
    Steinberg, Steven M.
    Manfro, Roberto
    Nainan, Georgy
    Vincenti, Flavio
    Jones-Burton, Charlotte
    Grinyo, Josep M.
    TRANSPLANT INTERNATIONAL, 2013, 26 : 44 - 44
  • [24] COMPARISON OF CLINICAL OUTCOMES FOR BELATACEPT VERSUS CALCINEURIN INHIBITOR AMONG DCD AND/OR HIGH KDPI KIDNEY TRANSPLANT RECIPIENTS
    Rizvi, Asim
    Nguyen, Thang
    Zill, Allison
    Kueht, Michael
    Rawala, Muhammad
    Gamilla-Crudo, Ann
    Hussain, Syed
    Mujtaba, Muhammad
    AMERICAN JOURNAL OF KIDNEY DISEASES, 2022, 79 (04) : S122 - S123
  • [25] THREE-YEARS OUTCOMES AFTER SWITCHING TO BELATACEPT FROM CALCINEURIN INHIBITOR IN STABLE KIDNEY TRANSPLANT RECIPIENTS
    Kamar, N.
    Rial, M.
    Alberu, J.
    Steinberg, S.
    Manfro, R.
    Nainan, G.
    Vicenti, F.
    Jones-Burton, C.
    Grinyo, J.
    TRANSPLANT INTERNATIONAL, 2013, 26 : 22 - 22
  • [26] Conversion from calcineurin inhibitor-based immunosuppression to mammalian target of rapamycin inhibitors or belatacept in renal transplant recipients
    Mulgaonkar, Shamkant
    Kaufman, Dixon B.
    CLINICAL TRANSPLANTATION, 2014, 28 (11) : 1209 - 1224
  • [27] INFLUENCE OF AGE AT CONVERSION TO EVEROLIMUS WITH CALCINEURIN INHIBITOR MINIMIZATION IN STABLE KIDNEY TRANSPLANT RECIPIENTS
    Uchida, Junji
    Nishide, Shunji
    Iwai, Tomoaki
    Kuwabara, Nobuyuki
    Kabei, Kazuya
    Kosoku, Akihiro
    Shimada, Hisao
    Yamasaki, Takeshi
    Kuratsuyuki, Katsuyuki
    Tanaka, Tomoaki
    Kumada, Norihiko
    Takemoto, Yoshiaki
    Nakatani, Tatsuya
    TRANSPLANT INTERNATIONAL, 2017, 30 : 473 - 473
  • [28] Urothelial carcinoma in kidney transplant recipients: Conversion from calcineurin inhibitor to proliferation signal inhibitor? Reply
    Nortier, Joelle Louise
    Lemy, Anne
    Wissing, Karl M.
    Abramowicz, Daniel
    Vanherweghem, Jean-Louis
    AMERICAN JOURNAL OF KIDNEY DISEASES, 2008, 52 (03) : 631 - 631
  • [29] LATE CONVERSION FROM CALCINEURIN INHIBITORS TO BELATACEPT IN KIDNEY TRANSPLANT RECIPIENTS HAS A SIGNIFICANT BENEFICIAL IMPACT ON GLYCEMIC PARAMETERS
    Terrec, F.
    Jouve, T.
    Naciri-Bennani, H.
    Benhamou, P. Y.
    Malvezzi, P.
    Janbon, B.
    Giovannini, D.
    Rostaing, L.
    Noble, J.
    TRANSPLANT INTERNATIONAL, 2020, 33 : 17 - 17
  • [30] Belatacept Conversion for Calcineurin Inhibitor (CNI) Toxicity: Our First 100 Patients
    Crew, R.
    Patel, S.
    Pai, A.
    Batal, I.
    Fernandez, H.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2017, 17 : 397 - 397
12345